

# High Value Care: Students want in too!

Kelly Bossenbroek Fedoriw, MD

UNC Family Medicine

October 5, 2019

# Objective

When you leave today you will have the tools to define high value care, explain why we strive for it, and model this care for a learner in a clinical setting

# Definition

Care that achieves patient oriented outcomes that outweigh the cost.

Key is shared decision making, conversations, connections with patients.

# Why does it matter?

You get what you pay for?

Limited resources

Wikipedia: Guinness World Record-holder [Owen Morse](#) juggling during a training session at [University of California, Irvine](#), in 1988



# Clinical Cases

Shared decision making

Groups of 2-3

3 min

# Yearly pap – 35 yr old woman

Seeing a new PCP. Previous PCP believed in the importance of yearly cervical cancer screening. Patient is requesting a pap smear today although her last one was 1 year ago and normal.

# Teaching?

Much of high value care is knowing what is evidence based and what is not

## Algorithms

Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors

American Society for Colposcopy and Cervical Pathology

Reprinted – August 2014

### Introduction

#### Cytology

Since the publication of the 2006 consensus guidelines, new cervical cancer screening guidelines have been published and new information has become available which includes key cervical cancer screening and follow up, and cervical precancer management data over a nine year period among more than 1 million women cared for at Kaiser Permanente Northern California. Moreover, women under age 21 are no longer receiving cervical cancer screening and cotesting with high-risk HPV type assays, and cervical cytology is being used to screen women 30 years of age and older.

Therefore, in 2012 the American Society for Colposcopy and Cervical Pathology (ASCCP), together with its 24 partner professional societies, Federal agencies, and international organizations, began the process of revising the 2006 management guidelines. This culminated in the consensus

conference held at the National Institutes of Health in September 2012. This report provides updated recommendations for managing women with cytological abnormalities. A more comprehensive discussion of these recommendations and their supporting evidence was published in the *Journal of Lower Genital Tract Disease and Obstetrics and Gynecology* and is made available on the ASCCP website at [www.asccp.org](http://www.asccp.org).

#### Histopathology

Appropriate management of women with histo-pathologically diagnosed cervical precancer is an important component of cervical cancer prevention programs. Although the precise number of women diagnosed with cervical precancer each year in the U.S. is not known, it appears to be a relatively common occurrence. In 2001 and 2006, the American Society for Colposcopy and Cervical Pathology and 28 partner professional societies, federal agencies, and international organizations, convened processes to develop and update consensus guidelines for the management of women with

cervical precancer. Since then, considerable new information has emerged about management of young women, and the impact of treatment for precursor disease on pregnancy outcomes. Progress has also been made in our understanding of the management of women with adenocarcinoma in-situ, also a human papillomavirus (HPV)—associated precursor lesion to invasive cervical adenocarcinoma. Therefore, in 2012 the ASCCP, together with its partner organizations, reconvened the consensus process of revising the guidelines. This culminated in the September 2012 Consensus Conference held at the National Institutes of Health. This report provides the recommendations developed for managing women with cervical precancer. A summary of the guidelines themselves—including the recommendations for managing women with cervical cytological abnormalities — are published in *JLGTD* and *Obstetrics & Gynecology*.

© Copyright, 2002, 2006, 2013 American Society for Colposcopy and Cervical Pathology. All rights reserved

### General Comments

Although the guidelines are based on evidence whenever possible, for certain clinical situations limited high-quality

The 2001 Bethesda System terminology is used for cytological classification. This terminology utilizes the terms low-grade

is not equivalent to histopathological CIN2,3. The current guidelines expand clinical indications for HPV testing based

# Back pain – 63 yr old woman

Patient with a 3 year history of chronic back pain with a normal physical exam and nonspecific MRI 2 years ago is requesting a new MRI. She is tired of being in pain and frustrated that it hasn't completely resolved after years of conservative management.



# Teaching?


Algorithms

Red Flags

Change your management



Low back pain and sciatica: summary of NICE guidance  
BMJ 2017; 356 doi: <https://doi.org/10.1136/bmj.i6748>



***Table.* Questions Physicians Should Ask Themselves Before Ordering Tests**

Did the patient have this test previously?

If so, what is the indication for repeating it? Is the result of a repeated test likely to be substantively different from the last result?

If it was done recently elsewhere, can I get the result instead of repeating the test?

Will the test result change my care of the patient?

What are the probability and potential adverse consequences of a false-positive result?

Is the patient in potential danger over the short term if I do not perform this test?

Am I ordering the test primarily because the patient wants it or to reassure the patient?

If so, have I discussed the above issues with the patient?

Are there other strategies to reassure the patient?

# Mammogram – 45 yr old woman

Patient without personal or family history of breast pathology who is requesting a mammogram for screening.


# Teaching?

Guidelines conflict – who do you go with?

The gray area is challenging

Use decision aids

## Screening 1000 women not at increased risk aged 40–49 over 7 years



With screening:

- 294 women will have a false positive test result
- 43 women will have an unnecessary biopsy
- 7 women will be diagnosed with breast cancer. Among these 7 women:
  - 3 will be treated for a breast cancer that would have never caused a problem
  - Less than 1 breast cancer death will be prevented

1724 women in this age group would need to be screened to prevent one death

# Tools and Tricks – ideas to share

AACE app – DM management algorithm

ACC apps – including lipids, anticoagulation and risk calculators

Repository of patient decision aids: <https://decisionaid.ohri.ca/AZlist.html>

Opioid converter app

Opioid calc app

Choosing wisely campaign - <https://www.choosingwisely.org/>

Kidneyfailurerisk.com

5 minute clinical consult – book or app

For more thoughtful listening: <https://www.thisamericanlife.org/391/more-is-less/act-two> and [https://shortcut.thisamericanlife.org/#/clipping/391/309?\\_k=wgtvk1](https://shortcut.thisamericanlife.org/#/clipping/391/309?_k=wgtvk1)

# Teaching High Value Care

Patient centered care in the midst of a population with limited resources

Modeling shared decision making

HVC shouldn't be reduced to metrics

# Another case

15 min visit

Chronic low back pain – needs oxycodone refills

DM – last A1C 3 months ago was 11.3

HTN – BP today is 156/92 on repeat

Due for flu shot and pneumovax, pt declines

Tobacco use – 1ppd, 40 pack yrs

# Teaching?

Think out loud

Things that are obvious to you are NOT always obvious to a learner



# Back to the case

15 min visit

Chronic low back pain – needs oxycodone refills

DM – last A1C 3 months ago was 11.3

HTN – BP today is 156/92 on repeat


Due for flu shot and pneumovax, pt declines

Tobacco use – 1ppd, 40 pack yrs



Unstable housing, partner who recently died in hospice care

# How do we balance the burden of treatment?



Who gets to determine the value? Patients?




# How High?





# How High?



# How High?



# How High?





# HVC on a larger scale





# Conclusion

Model shared decision making

Think out loud

Aim high

Let a learner be your inspiration

# References

Erath A, Mitchell M, Salwi S, Liu Y, Sherry A. The Sooner the Better. *Academic Medicine*. 9000;Publish Ahead of Print doi: 10.1097/ACM.0000000000002881.

Gupta R, Sehgal N, Arora VM. Aligning Delivery System and Training Missions in Academic Medical Centers to Promote High-Value Care. *Academic Medicine*. 2019;94(9):1289–1292. doi: 10.1097/ACM.0000000000002573.

Gupta R, Steers N, Moriates C, Wali S, Braddock CH, Ong M. High-Value Care Culture Among the Future Physician Workforce in Internal Medicine. *Academic Medicine*. 2019;94(9):1347–1354. doi: 10.1097/ACM.0000000000002619.

Moriates C, Valencia V, Stamets S, et al. Using Interactive Learning Modules to Teach Value-Based Health Care to Health Professions Trainees Across the United States. *Academic Medicine*. 2019;94(9):1332–1336. doi: 10.1097/ACM.0000000000002670.

Bhatia K, Chang EY, Abe T. Teaching High-Value Care Through Conscious Ordering of Diagnostic Tests. *JAMA Intern Med*. 2019;179(5):732. doi:10.1001/jamainternmed.2019.0017

Starr SR, Agrwal N, Leep Hunderfund AN. Rethinking the Cost of High-Value Care. *Academic Medicine*. 2019;94(6):747. doi: 10.1097/ACM.0000000000002683.

Laine C. High-Value Testing Begins With a Few Simple Questions. *Ann Intern Med*. 2012;156:162–163

Beach MC, Sugarman J. Realizing Shared Decision-making in Practice. *JAMA* Sept 3, 2019 811-812

Marcotte LM, Moriates C, Wolfson DB, Frankel RM. Professionalism as the Bedrock of High-Value Care. *Academic Medicine*. 9000;Publish Ahead of Print doi: 10.1097/ACM.0000000000002858.

Montori VM. Turning Away From Industrial Health Care Toward Careful and Kind Care. *Academic Medicine*. 2019;94(6):768–770. doi: 10.1097/ACM.0000000000002534.

<https://takingactiononoveruse.org/userfiles/TakingActiononOveruseFrameworkChangePackage.pdf>

Dobler C, et al. Treatment burden should be included in clinical practice guidelines. *BMJ* 2018; 363 doi <https://doi.org/10.1136/bmj.k4065>

Sherman J, MacNeill A, Thiel C. Reducing Pollution From the Health Care Industry. *JAMA* 2019; 322(11)1043-44.

Wellbery C, Sheffield P, Timmireddy K, Sarfaty M, Teherani A, Fallar R. It's Time for Medical Schools to Introduce Climate Change Into Their Curricula. *Academic Medicine*. 2018;93(12):1774–1777. doi: 10.1097/ACM.0000000000002368.